Md Anderson
Houston, Texas 77230-1402
39 studies enrolling now · 156 studies all time
What they study most
AML, AML (Acute Myelogenous Leukemia), AML (Acute Myeloid Leukemia), Acute Leukemia, Acute Leukemia (Category), Acute Lymphoblastic Leukemia, Acute Lymphoid Leukemia (ALL), Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), Adenocarcinoma of Esophagus, Adenoid Cystic Carcinoma
Studies at this site
- A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment — Recruiting now
- A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors — Recruiting now
- Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors — Recruiting now
- A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1) — Recruiting now
- Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML — Recruiting now
- A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation — Recruiting now
- Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia — Recruiting now
- A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs) — Recruiting now
- A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors — Recruiting now
- Metastatic Leiomyosarcoma Biomarker Protocol — Recruiting now
- Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study — Recruiting now
- A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types — Recruiting now
- TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II — Recruiting now
- Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment — Recruiting now
- Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment — Recruiting now
- Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) — Recruiting now
- A Study of TAK-505 in Adults With Solid Tumors — Recruiting now
- Acellular Dermal Matrix Investigation in Breast Reconstruction — Recruiting now
- QTX3034 in Patients With KRAS G12D Mutation — Recruiting now
- Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors — Recruiting now
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation — Recruiting now
- Psycho-Spiritual Management for Patients With Advanced Cancer and Their Family Caregivers — Recruiting now
- A Personalized Surveillance and Intervention Protocol for Patients With Familial Adenomatous Polyposis That Have Undergone (Procto)Colectomy — Recruiting now
- A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis — Recruiting now
- Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma — Recruiting now
- A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia — Recruiting now
- A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity — Recruiting now
- Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) — Recruiting now
- CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) — Recruiting now
- A Phase 1 Study of LNCB74 in Advanced Solid Tumors — Recruiting now
- Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer — Recruiting now
- A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL — Recruiting now
- Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients — Recruiting now
- A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. — Recruiting now
- Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML — Recruiting now
- LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge) — Recruiting now
- Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections — Recruiting now
- Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors — Recruiting now
- Ultrasound Imaging and Spectroscopy as Early Indicators of Locally-Advanced Breast Cancer Response — Recruiting now
- A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients — Starting soon
- Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL — Stopped early
- A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX — Completed
- A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors — Running, not enrolling
- A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies — Running, not enrolling
- Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) — Running, not enrolling
- HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903 — Completed
- CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors — Stopped early
- An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) — Running, not enrolling
- Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies — Available (expanded access)
- Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma — Completed